CVS Caremark®

|  |
| --- |
| Reference number(s) |
| 2159-A |

# Initial Prior Authorization

# New York Mandate Medicaid

# Specialty

## Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

| Brand Name |
| --- |
| Eligard (1966-A) |
| Fensolvi (3864-A) |
| Lupron-Depot Endometriosis-Fibroid (1970-A) |
| Lupron-Depot Ped (1972-A) |
| Lupron-Depot Prostate Ca (1971-A) |
| Supprelin La (1973-A) |
| Trelstar (1968-A) |
| Triptodur (2504-A) |
| Zoladex (1918-A) |

## Coverage Criteria

### Gender Dysphoria

Authorization may be granted for the patient’s diagnosis of gender dysphoria when ALL of the following criteria are met:

* The patient has experienced puberty to at least Tanner stage 2.
* The patient’s pubertal changes did result in an increase in gender dysphoria.
* The patient has been evaluated for psychiatric conditions that could interfere with the diagnostic work-up or treatment.
* The patient will have adequate psychological and social support during treatment.
* The patient does demonstrate knowledge and understanding of the expected outcomes of treatment with pubertal suppressants.
* The patient does demonstrate knowledge and understanding of the medical and social risks and benefits of sex reassignment.

## Duration of Approval (DOA)

* 2159-A: DOA: 12 months

## References

1. New York State Department of Health; Medicaid regulations at 18 NYCRR 505.2(l), December 2016.

## Document History

Written: Specialty Clinical Development (TS) 07/2017

Revised: PK 07/2018 (no changes per GSRA), CN 08/2019 (no changes per GSRA), LP 08/2021 (no clinical changed, added Fensolvi), (JK) 07/2022 (removed Vantas), 10/2022 (updated knowledge question to align with targeted agents), 02/2023 (no clinical changes), 03/2024 (no clinical changes), 03/2025 (no clinical changes)

Reviewed: CDPR/ MES 07/2017, GAD 07/2018, 08/2018, ME 08/2019, (CHART) 07/07/2022, 10/13/2022, 02/23/2023, 03/21/2024, 03/27/2025

External: 08/2017 (P&T, no external), 08/2018 (P&T, no external), 08/2022 (FYI), 09/2022, 10/2022, 04/2023 (FYI), 04/2024 (FYI), 04/2025 (FYI)